Contemporary Management of PV: Data Review and Case Challenges Illustrating Current Best Practices

Review strategies for community team management of polycythemia vera, including risk stratification directing cytoreductive therapy, dose optimization considering response and tolerance, and identification of factors directing treatment switch.

Share

Program Content

Activities

2023 PV Community Practice
A Community Practitioner’s Guide to Contemporary Management of Polycythemia Vera: Data Review and Case Challenges Illustrating Current Best Practice
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 25, 2023

Activities

2023 PV On Demand Webcast
A Community Practitioner’s Guide to Contemporary Management of Polycythemia Vera: Data Review and Case Challenges Illustrating Current Best Practice
Video
Congratulations: You achieved a completion on 04/09/2022

Released: November 06, 2023

Expires: November 05, 2024

Activities

PV FAQ 2023
Best Practices for Polycythemia Vera: Expert Answers to Frequently Asked Questions From the Community
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 19, 2023

Faculty

cover img faculity

Andrew Kuykendall, MD

Assistant Member
Department of Malignant Hematology
H. Lee Moffitt Cancer Center
Tampa, Florida

cover img faculity

John Mascarenhas, MD

Director
Center of Excellence in Blood Cancers and Myeloid Disorders
Director
Adult Leukemia Program
Leader
Myeloproliferative Disorders Clinical Research Program
Division of Hematology/Oncology
Tisch Cancer Institute
Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

cover img faculity

Douglas Tremblay, MD

Assistant Professor of Medicine
Department of Hematology and Oncology
Tisch Cancer Institute
Ichan School of Medicine 
New York, New York

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from PharmaEssentia USA Corporation and Incyte Corporation.

Incyte Corporation

PharmaEssentia USA Corporation